These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 21446779)

  • 1. Varespladib.
    Am J Cardiovasc Drugs; 2011; 11(2):137-43. PubMed ID: 21446779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease.
    Karakas M; Koenig W
    IDrugs; 2009 Sep; 12(9):585-92. PubMed ID: 19697278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
    Nicholls SJ; Kastelein JJ; Schwartz GG; Bash D; Rosenson RS; Cavender MA; Brennan DM; Koenig W; Jukema JW; Nambi V; Wright RS; Menon V; Lincoff AM; Nissen SE;
    JAMA; 2014 Jan; 311(3):252-62. PubMed ID: 24247616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of secretory phospholipase A(2) in patients with acute coronary syndromes: rationale and design of the vascular inflammation suppression to treat acute coronary syndrome for 16 weeks (VISTA-16) trial.
    Nicholls SJ; Cavender MA; Kastelein JJ; Schwartz G; Waters DD; Rosenson RS; Bash D; Hislop C
    Cardiovasc Drugs Ther; 2012 Feb; 26(1):71-5. PubMed ID: 22109255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.
    Rosenson RS; Elliott M; Stasiv Y; Hislop C;
    Eur Heart J; 2011 Apr; 32(8):999-1005. PubMed ID: 21081550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varespladib (LY315920) and Methyl Varespladib (LY333013) Abrogate or Delay Lethality Induced by Presynaptically Acting Neurotoxic Snake Venoms.
    Gutiérrez JM; Lewin MR; Williams DJ; Lomonte B
    Toxins (Basel); 2020 Feb; 12(2):. PubMed ID: 32093386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of sPLA2 and endothelial function: a substudy of the SPIDER-PCI trial.
    Lavi S; Thorpe K; Luca MC; Liuni A; Floras J; Horlick EM; Ing D; Osten MD; Overgaard CB; Lan J; Parker JD; Cantor WJ; Džavík V
    Can J Cardiol; 2012; 28(2):215-21. PubMed ID: 22281412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute coronary syndromes: targeting inflammation-what has the VISTA-16 trial taught us?
    O'Donoghue ML
    Nat Rev Cardiol; 2014 Mar; 11(3):130-2. PubMed ID: 24419257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Varespladib methyl in cardiovascular disease.
    Rosenson RS; Fraser H; Trias J; Hislop C
    Expert Opin Investig Drugs; 2010 Oct; 19(10):1245-55. PubMed ID: 20809869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-inflammatory effects of varespladib methyl in diabetic patients with acute coronary syndrome.
    Rosenson RS; Fraser H; Goulder MA; Hislop C
    Cardiovasc Drugs Ther; 2011 Dec; 25(6):539-44. PubMed ID: 21989792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Varespladib (LY315920) Appears to Be a Potent, Broad-Spectrum, Inhibitor of Snake Venom Phospholipase A2 and a Possible Pre-Referral Treatment for Envenomation.
    Lewin M; Samuel S; Merkel J; Bickler P
    Toxins (Basel); 2016 Aug; 8(9):. PubMed ID: 27571102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. After FRANCIS: next steps in the clinical evaluation of varespladib methyl.
    Rosenson RS
    Future Cardiol; 2011 Jan; 7(1):11-8. PubMed ID: 21174506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sPLA2 Inhibition to Decrease Enzyme Release after Percutaneous Coronary Intervention (SPIDER-PCI) trial.
    Džavík V; Lavi S; Thorpe K; Yip PM; Plante S; Ing D; Overgaard CB; Osten MD; Lan J; Robbins K; Miner SE; Horlick EM; Cantor WJ
    Circulation; 2010 Dec; 122(23):2411-8. PubMed ID: 21098449
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Varespladib (LY315920) inhibits neuromuscular blockade induced by Oxyuranus scutellatus venom in a nerve-muscle preparation.
    Fontana Oliveira IC; Gutiérrez JM; Lewin MR; Oshima-Franco Y
    Toxicon; 2020 Nov; 187():101-104. PubMed ID: 32889027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDS.
    De Luca D; Minucci A; Piastra M; Cogo PE; Vendittelli F; Marzano L; Gentile L; Giardina B; Conti G; Capoluongo ED
    PLoS One; 2012; 7(10):e47066. PubMed ID: 23071714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes.
    Rosenson RS
    Curr Opin Lipidol; 2010 Dec; 21(6):473-80. PubMed ID: 20739882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phospholipase A2 enzymes and the risk of atherosclerosis.
    Rosenson RS; Hurt-Camejo E
    Eur Heart J; 2012 Dec; 33(23):2899-909. PubMed ID: 22802388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Varespladib inhibits secretory phospholipase A2 in bronchoalveolar lavage of different types of neonatal lung injury.
    De Luca D; Minucci A; Trias J; Tripodi D; Conti G; Zuppi C; Capoluongo E;
    J Clin Pharmacol; 2012 May; 52(5):729-37. PubMed ID: 21602519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phospholipase A2 inhibitors in the treatment of atherosclerosis: a new approach moves forward in the clinic.
    Suckling KE
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1425-30. PubMed ID: 19691442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surfactant and varespladib co-administration in stimulated rat alveolar macrophages culture.
    De Luca D; Vendittelli F; Trias J; Fraser H; Minucci A; Gentile L; Perez-Gil J; Conti G; Antonelli M; Capoluongo ED
    Curr Pharm Biotechnol; 2013; 14(4):445-8. PubMed ID: 23590147
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.